Precision Optics Reports First Quarter Fiscal Year 2025 Financial Results
| Three Months | |||||||
| Ended September 30 | |||||||
| 2024 | 2023 | ||||||
| Revenues | $ | 4,197,053 | $ | 4,321,255 | |||
| Gross Profit | 1,117,330 | 1,463,611 | |||||
| Stock Compensation Expenses | 149,364 | 108,746 | |||||
| Other | 2,214,907 | 1,760,158 | |||||
| Total Operating Expenses | 2,364,271 | 1,868,904 | |||||
| Operating Income (Loss) | (1,246,941 | ) | (405,293 | ) | |||
| Net Income (Loss) | (1,311,247 | ) | (464,415 | ) | |||
| Income (Loss) per Share | |||||||
| Basic & Fully Diluted | $ | (0.21 | ) | $ | (0.08 | ) | |
| Weighted Average Common Shares Outstanding | |||||||
| Basic & Fully Diluted | 6,216,630 | 6,066,518 |
Conference Call Details
Date and Time: Thursday, November 14, at 5:00pm ET
Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or
(412) 317-5705.
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at .
Replay: A teleconference replay of the call will be available until November 21, 2024, at (877) 344-7529 or (412) 317-0088, replay access code 7879688. A webcast replay will be available at .
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company designs and manufactures next-generation product solutions for the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery, including single-use medical devices, as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies with a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit .
Non-GAAP Financial Measures
Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America (“non-GAAP”). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation AND DEPRECIATION, AMORTIZATION AND INTEREST EXPENSE.
This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.
About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. Forward-looking statements in this press release include, without limitation, future levels of expected product deliveries and projections related to future EBITDA goals. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous risk factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.
Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
...
| PRECISION OPTICS CORPORATION, INC. CONSOLIDATED BALANCE SHEETS (UNAUDITED) | ||||||||
| September 30, | June 30, | |||||||
| 2024 | 2024 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 635,572 | $ | 405,278 | ||||
| Accounts receivable, net of allowance for doubtful accounts of $103,224 at September 30, 2024 and $118,872 at June 30, 2024 | 3,123,595 | 3,545,491 | ||||||
| Inventories | 3,460,621 | 2,868,100 | ||||||
| Prepaid expenses | 288,475 | 299,364 | ||||||
| Total current assets | 7,508,263 | 7,118,233 | ||||||
| Fixed Assets: | ||||||||
| Machinery and equipment | 3,346,694 | 3,341,194 | ||||||
| Leasehold improvements | 819,954 | 810,914 | ||||||
| Furniture and fixtures | 426,234 | 416,425 | ||||||
| 4,592,882 | 4,568,533 | |||||||
| Less-accumulated depreciation and amortization | 4,123,250 | 4,074,960 | ||||||
| Net fixed assets | 469,632 | 493,573 | ||||||
| Operating lease right-to-use asset | 146,247 | 189,999 | ||||||
| Patents, net | 290,309 | 286,559 | ||||||
| Goodwill | 8,824,210 | 8,824,210 | ||||||
| Total other assets | 9,260,766 | 9,300,768 | ||||||
| TOTAL ASSETS | $ | 17,238,661 | $ | 16,912,574 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Revolving line of credit | $ | 500,000 | $ | 1,000,000 | ||||
| Current portion of capital lease obligation | 38,886 | 41,113 | ||||||
| Current maturities of long-term debt | 285,901 | 276,928 | ||||||
| Accounts payable | 2,143,351 | 1,397,313 | ||||||
| Contract liabilities | 1,106,546 | 1,172,350 | ||||||
| Accrued compensation and other | 1,115,135 | 840,662 | ||||||
| Operating lease liability | 146,247 | 178,450 | ||||||
| Total current liabilities | 5,336,066 | 4,906,816 | ||||||
| Capital lease obligation, net of current portion | 18,384 | 27,369 | ||||||
| Long-term debt, net of current maturities and debt issuance costs | 1,746,764 | 1,899,052 | ||||||
| Operating lease liability, net of current portion | - | 11,549 | ||||||
| Total liabilities | 7,101,214 | 6,844,786 | ||||||
| Stockholders' Equity: | ||||||||
| Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 6,350,170 shares at September 30, 2024 and 6,073,939 at June 30, 2024 | 63,502 | 60,739 | ||||||
| Additional paid-in capital | 62,575,576 | 61,197,433 | ||||||
| Accumulated deficit | (52,501,631 | ) | (51,190,384 | ) | ||||
| Total stockholders' equity | 10,137,447 | 10,067,788 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 17,238,661 | $ | 16,912,574 |
| PRECISION OPTICS CORPORATION, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (UNAUDITED) | ||||||||
| Three Months Ended September 30, | ||||||||
| 2024 | 2023 | |||||||
| Revenues | $ | 4,197,053 | $ | 4,321,255 | ||||
| Cost of Goods Sold | 3,079,723 | 2,857,644 | ||||||
| Gross Profit | 1,117,330 | 1,463,611 | ||||||
| Research and Development Expenses | 400,659 | 212,758 | ||||||
| Selling, General and Administrative Expenses | 1,963,612 | 1,656,146 | ||||||
| Total Operating Expenses | 2,364,271 | 1,868,904 | ||||||
| Operating Loss | (1,246,941 | ) | (405,293 | ) | ||||
| Interest Expense | (64,306 | ) | (59,122 | ) | ||||
| Net Loss | $ | (1,311,247 | ) | $ | (464,415 | ) | ||
| Loss Per Share: | ||||||||
| Basic & Fully Diluted | $ | (0.21 | ) | $ | (0.08 | ) | ||
| Weighted Average Common Shares Outstanding: | ||||||||
| Basic & Fully Diluted | 6,216,630 | 6,066,518 |
| PRECISION OPTICS CORPORATION, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (UNAUDITED) | ||||||||||||||||||||
| Three Month Period Ended September 30, 2024 | ||||||||||||||||||||
| Number of Shares | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Equity | ||||||||||||||||
| Balance, July 1, 2024 | 6,073,939 | $ | 60,739 | $ | 61,197,433 | $ | (51,190,384 | ) | $ | 10,067,788 | ||||||||||
| Issuance of common stock in registered direct offering | 265,868 | 2,659 | 1,201,883 | 1,204,542 | ||||||||||||||||
| Proceeds from exercise of stock option | 10,363 | 104 | 26,896 | 27,000 | ||||||||||||||||
| Stock-based compensation | – | – | 149,364 | – | 149,364 | |||||||||||||||
| Net loss | – | – | – | (1,311,247 | ) | (1,311,247 | ) | |||||||||||||
| Balance, September 30, 2024 | 6,350,170 | $ | 63,502 | $ | 62,575,576 | $ | (52,501,631 | ) | $ | 10,137,447 |
| Three Month Period Ended September 30, 2023 | ||||||||||||||||||||
| Number of Shares | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders' Equity | ||||||||||||||||
| Balance, July 1, 2023 | 6,066,518 | $ | 60,665 | $ | 60,224,934 | $ | (48,239,007 | ) | $ | 12,046,592 | ||||||||||
| Stock-based compensation | – | – | 108,746 | 108,746 | ||||||||||||||||
| Net loss | – | – | – | (464,415 | ) | (464,415 | ) | |||||||||||||
| Balance, September 30, 2023 | 6,066,518 | $ | 60,665 | $ | 60,333,680 | $ | (48,703,422 | ) | $ | 11,690,923 |
| PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES | |||||||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | |||||||||
| ADJUSTED EBITDA | |||||||||
| Three Months | |||||||||
| September 30, | |||||||||
| 2024 | 2023 | ||||||||
| Net Income (loss) (GAAP) | $ | (1,311,247 | ) | $ | (464,415 | ) | |||
| Stock based compensation | 149,364 | 108,746 | |||||||
| Depreciation and amortization | 48,290 | 51,564 | |||||||
| State Income Taxes | - | - | |||||||
| Interest expense | 64,306 | 59,122 | |||||||
| Adjusted EBITDA (non-GAAP) | $ | (1,049,287 | ) | $ | (244,983 | ) | |||

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment